MERIT-HF研究PPT课件.ppt

《MERIT-HF研究PPT课件.ppt》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。

1、MERIT-HF:MetoprololCR/XLRandomizedInterventionTrialincongestiveHeartFailurePurposeTodeterminewhethermetoprololcontrolled/extendedrelease(CR/XL)oncedaily,inadditiontostandardtherapy,canlowermortalityinpatientswithdecreasedejectionfractionandsymptomsofheart

2、failureReferenceMERIT-HFStudyGroup.EffectofmetoprololCR/XLinchronicheartfailure:MetoprololCR/XLRandomisedInterventionTrialinCongestiveHeartFailure(MERIT-HF).Lancet1999;353:2001–7.MERIT-HF:MetoprololCR/XLRandomizedInterventionTrialincongestiveHeartFailure-

3、TRIALDESIGN-DesignRandomized,double-blind,placebo-controlledPatients3991patientswithleftventricularejectionfraction<0.40andNYHAclassII-IVheartfailure,stabilizedbyoptimumstandardtherapy(anycombinationofdiuretics+ACEinhibitor)FollowupandprimaryendpointAim2.

4、4yearsfollowup.Primaryendpointall-causemortalityTreatmentPatientsassignedmetoprololreceived12.5(NYHAIII-IV)or25mg(NYHAII)oncedaily,increasingover8weekstomaximumtargetdose200mgoncedailyMERIT-HF:MetoprololCR/XLRandomizedInterventionTrialincongestiveHeartFai

5、lure-RESULTS-Studyhaltedatmeanfollowupof1yearonrecommendationofindependentsafetycommitteebecausepredefinedcriteriametandexceeded:All-causemortalitysignificantlylowerinmetoprololCR/XLgroup(145vs.217,34%riskreduction,P=0.0062)Significantlyfewercardiovascula

6、rdeaths(128vs.203),suddendeaths(79vs.132)anddeathfromworseningheartfailure(30vs.58)Drugwelltolerated,asdefinedbypermanentearlydiscontinuationoftreatment(13.9%ofmetoprololCR/XLgroupversus15.3%placebo)MERIT-HF:MetoprololCR/XLRandomizedInterventionTrialincon

7、gestiveHeartFailure-RESULTScontinued-MERIT-HFStudyGroup.Lancet1999;353:2001–7.NopatientslosttofollowupMERIT-HFtrialprofile3991patientsrandomized2001patientsplacebo217patientdeaths1784patientsalive1539patientsontreatment145patientdeaths1990patientsmetoprol

8、olCR/XL1845patientsalive1614patientsontreatmentMERIT-HF:MetoprololCR/XLRandomizedInterventionTrialincongestiveHeartFailure-RESULTScontinued-Cumulativeall-causemortalityMERIT-HFStudyGroup.Lancet1999;353:2001–7.Follow